Park Avenue Securities LLC Purchases 7,789 Shares of Globus Medical, Inc. $GMED

Park Avenue Securities LLC boosted its position in shares of Globus Medical, Inc. (NYSE:GMED) by 45.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,034 shares of the medical device company’s stock after acquiring an additional 7,789 shares during the period. Park Avenue Securities LLC’s holdings in Globus Medical were worth $1,875,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Elevation Wealth Partners LLC grew its holdings in Globus Medical by 2,178.6% in the second quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock worth $25,000 after purchasing an additional 305 shares during the last quarter. Continuum Advisory LLC acquired a new position in shares of Globus Medical during the second quarter worth $25,000. Root Financial Partners LLC purchased a new stake in shares of Globus Medical during the 3rd quarter valued at $29,000. Summit Securities Group LLC purchased a new stake in shares of Globus Medical during the 1st quarter valued at $48,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Globus Medical by 111.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,199 shares of the medical device company’s stock valued at $103,000 after purchasing an additional 632 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised EPS estimates across multiple periods, including Q3 2026 to $1.19, FY2026 to $4.98, FY2027 to $5.07, and FY2028 to $5.89. The firm also lifted estimates for Q1 2027, Q2 2027 and Q2 2028 by $0.01 each and maintained a “Strong-Buy” rating. The revisions suggest modestly improving expectations for Globus Medical’s earnings outlook. MarketBeat Globus Medical analyst estimates
• Positive Sentiment: Globus Medical was highlighted as a healthcare technology stock positioned for digital-health growth. Zacks cited projected 2026 earnings growth, an attractive valuation and innovation in essential medical services as reasons the company could benefit from broader healthcare technology adoption. Zacks healthcare technology stocks article
• Positive Sentiment: Another analysis called GMED undervalued even after a 77% run. This supports the view that analysts see additional upside based on Globus Medical’s earnings prospects and valuation, although the large prior gain may also encourage profit-taking. Globus Medical stock looks undervalued article
• Neutral Sentiment: The estimate increases were small—generally just $0.01 per share—and Zacks’ FY2026 estimate of $4.98 remains slightly below the broader consensus of $4.99. As a result, the revisions provide incremental support but may not be strong enough to overcome near-term selling pressure.
• Negative Sentiment: With GMED having already advanced substantially, investors may be locking in gains while waiting for a larger earnings or guidance catalyst. This profit-taking dynamic appears to be outweighing the otherwise favorable analyst commentary today.

Globus Medical Stock Performance

Globus Medical stock opened at $77.98 on Friday. The business’s 50-day simple moving average is $77.64 and its two-hundred day simple moving average is $83.51. The company has a market cap of $10.47 billion, a PE ratio of 19.94, a PEG ratio of 1.26 and a beta of 0.96. Globus Medical, Inc. has a fifty-two week low of $59.51 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The company’s revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, analysts predict that Globus Medical, Inc. will post 4.99 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GMED. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research report on Friday, October 9th. BMO Capital Markets began coverage on Globus Medical in a research report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 target price on the stock. Stifel Nicolaus decreased their price target on Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research note on Wednesday, July 8th. Wells Fargo & Company lowered their price target on Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Finally, Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and an average price target of $99.46.

Insider Buying and Selling

In other Globus Medical news, Director James R. Tobin sold 30,000 shares of Globus Medical stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the sale, the director directly owned 15,000 shares in the company, valued at approximately $1,118,700. The trade was a 66.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Stephen Zarrilli sold 25,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares in the company, valued at $2,176,000. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 18.38% of the company’s stock.

Globus Medical Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.